Press Release From Business Wire: Agendia, Inc.
Mohammad Ali (@ChaudhryMAli88) Published June 05, 2021 | 05:20 PM
IRVINE, June 5 (UrduPoint / Pakistan Point News - 5th Jun, 2021 ) :Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting in an oral presentation. The presentation will detail an additional risk threshold previously established within the MammaPrint Low Risk category, identifying patients with an Ultra Low Risk of distant recurrence, essentially meaning the patient's tumor is very unlikely to recur or metastasize over at least 20 years of follow-up, according to prior studies. This information could be helpful in further tailoring adjuvant treatment for patients with early stage breast cancer.
In the oral presentation, titled "Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial," Josephine Lopes Cardozo, MD, first author of the abstract, PhD Candidate at the Netherlands Cancer Institute and fellow at the EORTC, will outline that in the MINDACT study, patients with an UltraLow Risk signature have an excellent prognosis, with 8-year breast cancer specific survival above 99% regardless of clinical risk status, and an 8-year distant metastasis free interval of 97%. The presentation, part of ASCO 2021's Breast Cancer track, can be accessed here.
"The Ultra Low threshold identifies patients who may be candidates for further de-escalation of treatment," said Dr. Lopes Cardozo. "To give the patient's care team this kind of prognostic insight at the time of diagnosis will hopefully allow for many patients to avoid over treatment and further reduce the risk of side effects while maintaining excellent survival." The MINDACT trial, an independent, phase III, prospective, randomized clinical trial sponsored by the European Organization for Research and Treatment of Cancer (EORTC), was conducted with the Primary goal of determining whether Agendia's 70-gene MammaPrint� test could be used to de-escalate clinically high risk patients with early stage breast cancer from chemotherapy treatment. The study enrolled nearly 7,000 patients with newly-diagnosed breast cancer, and at median long-term follow-up of 8.
7 years, 46% of clinically high risk patients with a MammaPrint Low Risk result could forgo chemotherapy without negatively affecting their outcomes. These data were recently published in The Lancet Oncology.
The current study to be presented at ASCO focuses on the clinical characteristics and outcomes of the 1,000 women with a MammaPrint Ultra Low risk status enrolled in MINDACT. Consistent with three prior studies presented since 2017, these data show a nearly 100% breast cancer specific survival at 8 years, with 5 years of anti-estrogen therapy, and excellent outcomes (97.8% DMFI) for the 157 Ultra Low Risk women who received no systemic therapy.
"The confirmation of the clinical importance and excellent prognosis of the MammaPrint Ultra Low Risk category provides further support for the inclusion of this information in the management of endocrine therapy, particularly for those women experiencing severe side effects, and struggling to remain on their prescribed treatment," said William Audeh, MD, Chief Medical Officer at Agendia. "We are extremely proud to have contributed to the EORTC's MINDACT study, which has influenced the clinical treatment of patients and will inspire ongoing translational research that will contribute to the library of data we need to personalize the treatment of breast cancer." Beyond answering the traditional adjuvant chemotherapy question, the MINDACT study continues to produce a wealth of insights with immediately meaningful clinical implications and access to an unprecedented full genome dataset for further research, resulting in widespread health system cost savings.
At ASCO 2021, Agendia also presented a larger suite of data from the company's groundbreaking FLEX registry, a large-scale, prospective, observational breast cancer study using whole transcriptome sequencing, recruiting patients from various ethnicities, ages and genders representative of the total breast cancer population as part of an ongoing effort to increase representation of diverse populations and data in clinical trials.
Related Topics
Recent Stories
Robinson, bowlers help New Zealand go 2-1 up against Pakistan
Shahzeb Chachar to hold khuli kachehri on April 26
Heatwave amid Israel's aggression in Gaza brings new misery, disease risk
Tourism must change, mayor says as Venice launches entry fee
Court adjourns Judicial Complex attack case till May 17
Nasreen Noori’s book ‘Popatan Jahra Khwab’ launched
Wafaqi Mohtasib inspection team visits Excise and taxation office
AJLAC announces 5th Conference titled ‘People’s Mandate: Safeguarding Civil ..
Pak-US officials engage to enhance trade, investment ties
IBCC to promote educational excellence, expand regional presence
Pakistani 'Blue Helmets' serving UN Peacekeeping Mission in DR Congo set to leav ..
Putin says plans to visit China in May
More Stories From Miscellaneous
-
PDMA predicts gusty wind, rain with thunder, hails
2 days ago -
Iranian president Raisi given guard of honour at PM House
4 days ago -
Intellectuals, writers accolades Naseer Mirza on his literary contribution
4 days ago -
Bahawalpur Adabi Sangat hosts memorable mushaira
4 days ago -
Cattle farming vital to alleviate poverty in rural areas
4 days ago -
Pakistan: A land of tourism, archeological wonders
5 days ago
-
Transforming education sector: from job hunters to job creators
7 days ago -
Amjad Bobby remembered on 19th death anniversary for timeless contributions to music
11 days ago -
Legendary actor Nadeem’s 26 films released on Eid-ul-Fitr days in 50 years
11 days ago -
Besant Hall Cultural Centre to celebrate evening with Sanam Marvi on 26 April
12 days ago -
Radio Bahawalpur presents program “Eidi Shidi”
14 days ago -
Radio Bahawalpur to broadcast Eid programs
17 days ago